Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Voltage-gated potassium channel, HERG (KCNH2)-related. C. elegans unc-103 ortholog | 0.0427 | 0.3589 | 1 |
Echinococcus multilocularis | voltage gated potassium channel | 0.0124 | 0.0563 | 0.1145 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0427 | 0.3589 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0371 | 0.3026 | 0.2905 |
Loa Loa (eye worm) | hypothetical protein | 0.0124 | 0.0563 | 0.0398 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0124 | 0.0563 | 0.1414 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0466 | 0.398 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.107 | 1 | 1 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0124 | 0.0563 | 0.1414 |
Toxoplasma gondii | hypothetical protein | 0.107 | 1 | 0.5 |
Loa Loa (eye worm) | voltage and ligand gated potassium channel | 0.0427 | 0.3589 | 0.3477 |
Loa Loa (eye worm) | hypothetical protein | 0.107 | 1 | 1 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0399 | 0.3309 | 1 |
Schistosoma mansoni | cyclic-nucleotide-gated cation channel | 0.0084 | 0.0171 | 0.043 |
Schistosoma mansoni | cyclic-nucleotide-gated cation channel | 0.0084 | 0.0171 | 0.043 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0124 | 0.0563 | 0.1145 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0084 | 0.0171 | 0.043 |
Loa Loa (eye worm) | inward rectifying k channel family protein 1 | 0.107 | 1 | 1 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0427 | 0.3589 | 1 |
Schistosoma mansoni | cyclic-nucleotide-gated cation channel | 0.0084 | 0.0171 | 0.043 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0466 | 0.398 | 1 |
Echinococcus granulosus | voltage gated potassium channel | 0.0124 | 0.0563 | 0.1145 |
Brugia malayi | Voltage-gated potassium channel, EAG (KCNH1)-related. C. elegans egl-2 ortholog | 0.0124 | 0.0563 | 0.1145 |
Schistosoma mansoni | hyperpolarization activated cyclic nucleotide-gated potassium channel | 0.0084 | 0.0171 | 0.043 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0399 | 0.3309 | 1 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0124 | 0.0563 | 0.1145 |
Schistosoma mansoni | hyperpolarization activated cyclic nucleotide-gated potassium channel | 0.0084 | 0.0171 | 0.043 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 11.6891 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 13.1154 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 29.081 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS assay for re-activators of p53 using a Luc reporter. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504709] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PubChem BioAssay. qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.